The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab

Infliximab (IFX) concentrations are a predictive factor (PF) of pharmacokinetic (PK) origin in the treatment of Crohn’s disease (CD). We evaluated Clearance, another PF of PK origin, either alone or in combination with concentrations. They were evaluated from two cohorts, the first designed to recei...

Full description

Bibliographic Details
Main Authors: Marla C. Dubinsky, Shervin Rabizadeh, John C. Panetta, Elizabeth A. Spencer, Annelie Everts-van der Wind, Thierry Dervieux
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Pharmaceutics
Subjects:
infliximab
Crohn’s disease
pharmacokinetics
clearance
predictive factors
Online Access:https://www.mdpi.com/1999-4923/15/10/2408

Similar Items

Similar Items